BFG
REGN icon

Baron Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Baron Financial Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-20
Closed -$11.8K – 161
2022
Q2 		$11.8K Hold
20
– – 0.01% 142
2022
Q1 		$14K Hold
20
– – 0.01% 150
2021
Q4 		$12.6K Hold
20
– – 0.01% 159
2021
Q3 		$12.1K Hold
20
– – 0.01% 162
2021
Q2 		$11.2K Hold
20
– – 0.01% 168
2021
Q1 		$9.46K Hold
20
– – 0.01% 173
2020
Q4 		$9.66K Hold
20
– – 0.01% 176
2020
Q3 		$11.2K Buy
+20
New +$12.1K 0.01% 165

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baron Financial Group's REGN Position: Q3 2022 in Review

Baron Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 20 shares — an estimated $11.8K sold.

Baron Financial Group first reported a position in REGN in Q3 2020 and held it in 8 quarters. The position peaked at $14K in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

  • Baron Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Baron Financial Group sold 20 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $11.8K.
  • Baron Financial Group first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 8 quarters.
  • Baron Financial Group's Regeneron Pharmaceuticals position peaked at $14K in Q1 2022.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Baron Financial Group's 13F filing for Q3 2022, filed 3 Nov 2022.